Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12847523.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Conventional gene therapy of hemophilia A relies on the transfer of factor VIII (FVIII; encoded by the F8 gene) cDNA. We carried out spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutant FVIII mRNA. A pre-trans-splicing molecule (PTM) corrected endogenous FVIII mRNA in F8 knockout mice with the hemophilia A phenotype, producing sufficient functional FVIII to correct the hemophilia A phenotype. This is the first description of phenotypic correction of a genetic defect by RNA repair in a knockout animal model. Our results indicate the feasibility of using SMaRT to repair RNA for the treatment of genetic diseases.
Medical subject headings
- Factor VIII
- Genetic Therapy
- Hemophilia A
- Phenotype
- RNA Splicing
- Spliceosomes